Respiratory Disease Testing Market to Grow with a CAGR of 5.72% through 2030F

According to TechSci Research report, “Respiratory Disease Testing Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2020–2030F”, the Global Respiratory Disease Testing Market stood at USD 6.01 Billion in 2024 and is anticipated to grow with a CAGR of 5.72% in the forecast period. The growth in the market can be attributed to the increasing prevalence of respiratory diseases, rising demand for point-of-care testing, and technological advancements in respiratory disease testing devices. The increasing prevalence of respiratory diseases is a significant driver of market growth. Factors such as the rising number of smokers, alcohol consumption, sedentary lifestyles, and stressful routines have led to an increase in cases of COPD and other severe respiratory conditions like lung cancer. The technological advancements in respiratory diagnostic testing, including the utilization of Internet of Things (IoT) and Artificial Intelligence (AI) for COPD diagnosis and outpatient management, have positively impacted market growth. There is a growing demand for respiratory diagnostic devices in privately-owned hospitals and healthcare centers, and both government and non-governmental organizations (NGOs) are making efforts to ensure access to quality healthcare facilities. The market is further propelled by enhanced research and development (R&D), a rising geriatric population, rapid urbanization, increasing industrial establishments, and escalating pollution levels worldwide.

The market for respiratory disease testing is further boosted by the rising pollution in the environment. Lungs are increasingly affected by various detrimental habits adopted by people worldwide, such as smoking and excessive alcohol consumption. In the US, cigarette smoking is a major risk factor for lung diseases, contributing to 80-90% of deaths. Similarly, low and middle-income countries experience 90% of deaths related to chronic obstructive pulmonary disease (COPD). Therefore, the rising prevalence of respiratory diseases will continue to drive the respiratory disease testing market. Technological advancements represent a key trend gaining popularity in the respiratory disease testing market. Major companies in this field are focused on developing artificial intelligence and machine learning technologies to optimize treatment protocols and improve patient outcomes, thereby strengthening their market position.

It aids in the early diagnosis and management of chronic obstructive pulmonary disease (COPD), asthma, and COVID-19, providing real-time feedback on lung function through advanced AI algorithms analyzing breath sounds. In January 2023, CAIRE Inc., a US-based medical supply and manufacturing company, acquired MGC Diagnostics Holdings to expand its product line and diversify its income sources by incorporating cardiorespiratory diagnostic products into its portfolio. This strategic move aims to solidify CAIRE Inc.'s position as a market leader in medical technology for respiratory and cardiorespiratory diagnostics. MGC Diagnostics Holdings Inc., a US-based medical technology company, specializes in providing cardiorespiratory diagnostic solutions and respiratory disease testing products.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Respiratory Disease Testing Market”

The Global Respiratory Disease Testing Market is segmented into test type, application, end user, regional distribution, and company.

Based on application, Chronic Obstructive Pulmonary Disease (COPD) was the dominant condition driving the global respiratory disease testing market. This prominence is due to COPD's high global prevalence, progressive nature, and strong association with long-term exposure to risk factors such as smoking, air pollution, and occupational hazards. According to the World Health Organization, COPD is among the leading causes of death worldwide, with millions affected across both high-income and low- to middle-income countries. The disease often requires regular monitoring and early detection, fueling demand for diagnostic tools like spirometry, imaging, and molecular testing. While lung cancer, asthma, and tuberculosis also contribute significantly to the respiratory diagnostics market, COPD's chronic and widespread nature positions it as a primary focus for healthcare systems and diagnostic companies. The growing aging population further exacerbates the burden of COPD, making it a key target for screening initiatives, research funding, and technological advancements in respiratory disease testing.

Based on region, Asia-Pacific is the fastest-growing region in the global respiratory disease testing market due to a combination of demographic, environmental, and healthcare system factors. The region faces a high burden of respiratory diseases such as COPD, asthma, tuberculosis, and increasing cases of lung cancer, largely driven by rising air pollution, rapid urbanization, and high smoking rates. Countries like China and India have some of the world's highest rates of air pollution, which directly contributes to chronic respiratory conditions. The large and aging population in many Asia-Pacific countries increases susceptibility to respiratory illnesses, creating greater demand for diagnostic solutions. Government initiatives to strengthen healthcare infrastructure, improve early disease detection, and invest in public health awareness are accelerating market growth. The increasing adoption of advanced diagnostic technologies and growing investments by international and regional diagnostic companies are expanding access to testing services. These combined factors make Asia-Pacific a key growth engine in the respiratory diagnostics market.

Major companies operating in Global Respiratory Disease Testing Market are:

·         Beckton Dickinson and Company

·         Koninklijke Philips N.V.

·         ResMed Inc.

·         Medtronic PLC

·         Carestream Health Inc.

·         MG Diagnostic Corporation

·         Abbott Laboratories Ltd.

·         ThermoFisher Scientific Inc.

·         Biomerieux Inc.

·         QIAGEN NV

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The global respiratory disease testing market has experienced notable growth in recent years, driven by the rising prevalence of conditions such as asthma, COPD, and lung cancer. Factors like pollution, smoking, and aging populations have contributed to this increase, boosting demand for accurate diagnostic solutions. Technological advancements, including molecular diagnostics, immunoassays, and advanced imaging, have significantly improved test accuracy and efficiency. These innovations support early detection, timely intervention, and personalized treatment strategies, ultimately enhancing patient outcomes. As awareness and healthcare infrastructure improve globally, the demand for effective respiratory testing continues to rise, reinforcing the market’s ongoing expansion and development”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com